Regulus Therapeutics Inc (RGLS)
2.65
-0.04
(-1.49%)
USD |
NASDAQ |
May 03, 16:00
2.65
0.00 (0.00%)
After-Hours: 20:00
Regulus Therapeutics Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2020 | 5.00M |
| September 30, 2020 | 5.00M |
| June 30, 2020 | |
| March 31, 2020 | 0.006M |
| December 31, 2019 | 0.018M |
| September 30, 2019 | 0.018M |
| June 30, 2019 | 0.018M |
| March 31, 2019 | 6.778M |
| December 31, 2018 | 0.018M |
| September 30, 2018 | 0.018M |
| June 30, 2018 | 0.018M |
| March 31, 2018 | 0.018M |
| December 31, 2017 | 0.018M |
| September 30, 2017 | 0.018M |
| June 30, 2017 | 0.018M |
| March 31, 2017 | 0.018M |
| December 31, 2016 | 0.018M |
| September 30, 2016 | 0.204M |
| June 30, 2016 | 0.483M |
| Date | Value |
|---|---|
| March 31, 2016 | 0.489M |
| December 31, 2015 | 10.86M |
| September 30, 2015 | 1.865M |
| June 30, 2015 | 3.834M |
| March 31, 2015 | 4.20M |
| December 31, 2014 | 4.219M |
| September 30, 2014 | 1.083M |
| June 30, 2014 | 0.736M |
| March 31, 2014 | 1.631M |
| December 31, 2013 | 5.454M |
| September 30, 2013 | 6.118M |
| June 30, 2013 | 4.759M |
| March 31, 2013 | 3.238M |
| December 31, 2012 | 3.238M |
| September 30, 2012 | 2.809M |
| June 30, 2012 | 3.309M |
| March 31, 2012 | 3.344M |
| December 31, 2011 | 3.363M |
| September 30, 2011 | 3.809M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.006M
Minimum
Mar 2020
5.00M
Maximum
Sep 2020
1.677M
Average
0.018M
Median
Jun 2019
Revenue (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 231.04M |
| ADMA Biologics Inc | 73.90M |
| FibroGen Inc | 27.14M |
| Protara Therapeutics Inc | -- |
| Amylyx Pharmaceuticals Inc | 108.45M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.061M |
| Total Expenses (Quarterly) | 8.30M |
| EPS Diluted (Quarterly) | -0.39 |
| Enterprise Value | 151.06M |
| Earnings Yield | -59.62% |
| Normalized Earnings Yield | -207.55 |